Answers are grounded in this paper and cite their sources.
A traceless O -acyl hydroxamate Fc-binding peptide linker enables rapid, scavenger-free, and site-selective conjugation at Lys248 of human IgG 1 . The resulting homogeneous DAR2 antibody–drug conjugates (ADCs) retain antigen binding and internalization with payload-dependent stability and cytotoxicity. The linker’s intrinsic leaving-group mechanism ensures clean FcBP release and broad payload compatibility. This robust, scalable traceless Lys248 conjugation chemistry underpins investigational new drug (IND)-approved and nonclinical ADC pipelines, offering a predictable platform for next-generation ADC design.
No takes yet. Share an insight, caveat, or question.
Son et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: